Study of chemotherapy combination for advanced solid tumors
Author Information
Author(s): Kosmas C, Tsavaris N B, Polyzos A, Malamos N A, Katsikas M, Antonopoulos M J
Primary Institution: Department of Medicine, Medical Oncology Unit, Helena-Venizelou Hospital
Hypothesis
We sought to evaluate the paclitaxel-ifosfamide-cisplatin (PIC) combination in the outpatient setting in individuals with a variety of advanced solid tumours.
Conclusion
The PIC regimen appears to be feasible and safe in the outpatient setting.
Supporting Evidence
- The regimen was tolerated with outpatient administration in 36/42 patients.
- Toxicities included grade 4 neutropenia for ≤ 5 days in 27% of cycles.
- The response rate was 47.5% (complete response + partial response: 20/42).
- Phase II studies are starting in non-small-cell lung cancer, ovarian cancer and head and neck cancer.
Takeaway
Doctors tested a new combination of cancer drugs on patients with advanced tumors, and it seemed to work well and be safe.
Methodology
Patients were entered into six successive dose levels with specific drug doses and were monitored for tolerability and side effects.
Limitations
The maximum tolerated dose was not formally reached, and care should be paid to neurotoxicity.
Participant Demographics
Eighteen patients had 2–8 cycles of prior chemotherapy with no taxanes or ifosfamide.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website